Skip to main content
search

Late Clinical

Sign up

Latest resources

Featured resource

Upcoming late clinical webinars

Latest late clinical blogs

Meet our experts at the following events

Conference

PHUSE APAC Connect 2026

February 19 - 21, 2026 – Hyderabad, India
Conference

16th Annual World ADC London 2026

February 23 - 26, 2026
Live Events

Certara IQ™ Global Roadshow

Certara IQ™ is going on the road. From APAC to Europe to North America, our experts are bringing hands-on, indepth

All late clinical resources

Predicted Heart Rate Effect of Inhaled LABA PF-00610355 in Volunteers and COPD Patients

Cardiovascular, Model Informed Drug Development, Modeling and Simulation - PK/PD, pre-update, Therapeutic Specialties, Publication

Prediction of Overall Survival or Progression Free Survival by Disease Control Rate at Week 8 Is Independent of Ethnicity: Western Versus Chinese Patients with First-line Non-small Cell Lung Cancer Treated with Chemotherapy with or without Bevacizumab

Model Informed Drug Development, Modeling and Simulation - PK/PD, Oncology/Hematology, pre-update, Therapeutic Specialties, Publication

Influence of Chronic Hepatitis C Infection on Cytochrome P450 3A4 Activity Using Midazolam as an In Vivo Probe Substrate

Infectious Disease, Modeling and Simulation - PK/PD, pre-update, Publication

Differential Pharmacokinetics of Ganitumab in Patients with Metastatic Pancreatic Cancer Versus Other Advanced Solid Cancers

Model Informed Drug Development, Modeling and Simulation - PK/PD, Oncology/Hematology, pre-update, Therapeutic Specialties, Publication

Exposure-response Analysis of Pertuzumab in HER2-positive Metastatic Breast Cancer: Absence of Effect on QTc Prolongation and Other ECG Parameters

Model Informed Drug Development, Modeling and Simulation - PK/PD, Oncology/Hematology, pre-update, Therapeutic Specialties, Publication

Using Historical Control Information for the Design and Analysis of Clinical Trials with Overdispersed Count Data

Central Nervous System (CNS), Certara Services, Model Informed Drug Development, Model-Based Meta-Analysis (MBMA), pre-update, Therapeutic Specialties, Publication

Siponimod for Patients with Relapsing-remitting Multiple Sclerosis (BOLD): An Adaptive, Dose-ranging, Randomized, Phase 2 Study

Central Nervous System (CNS), Model Informed Drug Development, Modeling and Simulation - PK/PD, pre-update, Therapeutic Specialties, Publication

Temporal Profile of Lymphocyte Counts and Relationship with Infections with Fingolimod Therapy

Model Informed Drug Development, pre-update, Publication

Pharmacokinetic-pharmacodynamic Determinants of Oseltamivir Efficacy Using Data from Phase 2 Inoculation Studies

Infectious Disease, Modeling and Simulation - PK/PD, pre-update, Publication

Clinical Trial Simulation to Inform Phase 2: Comparison of Concentrated vs. Distributed First-in-patient Study Designs in Psoriasis

Certara Services, Clinical Trials, Model Informed Drug Development, Model-Based Meta-Analysis (MBMA), Modeling and Simulation - PK/PD, pre-update, Publication

A Randomised Study of the Effect of Danoprevir/Ritonavir or Ritonavir on Substrates of Cytochrome P450 (CYP) 3A and 2C9 in Chronic Hepatitis C Patients Using a Drug Cocktail

Infectious Disease, Modeling and Simulation - PK/PD, pre-update, Publication

Model-based Drug Development: A Rational Approach to Efficiently Accelerate Drug Development

Model Informed Drug Development, Modeling and Simulation - PK/PD, pre-update, Publication
Sign up to newsletter

Why sign up? Because transforming drug development is not just our goal—it’s our obsession. If it’s yours too, then be the first to know of new insights and join us in pushing the boundaries of science.